Alexandria Real Estate's unique laboratory space assets are generating income.

Alexandria has successfully completed the sale of Labspace®'s non-nuclear assets in the Greater Boston region.

Alexandria is an important player in the $5+ trillion life science industry, which is poised for continued secular growth.

Alexandria tenants rely on the company's infrastructure to provide 24/7 operations for a life science industry that thrives on densely populated campuses and cannot operate from remote access.

Alexandria Real Estate Equities, Inc.

First, most experienced and innovative owner, manager and developer of research, agritech and advanced technology campuses at AAA Innovation Cluster locations.

Alexandria has been in operation since 1994,' 'when they invented and created the new Labspace® model.

Alexandria is the only publicly traded REIT focused on laboratory real estate.

The company has built a concentrated portfolio of assets from leading life science markets and has become the leading infrastructure platform for the industry.

Alexandria has successfully executed an internal and external growth strategy that has delivered outstanding long-term shareholder returns.

Alexandria sold five non-anchored properties in Greater Boston totaling 428,663 RSF at a price of $365 million.

The average sale price was $852 per RSF.

This transaction allowed the company to realize a gain on sale of $187.2 million and create additional value' 'in the amount of 80%.

The money raised from this transaction will be reinvested in the company's plan to develop new real estate properties for leading life science companies such as Eli Lilly, Bristol Myers Squibb and Moderna.

The company has a strong financial position, flexible balance sheet and high liquidity.

They also increased their stock dividend and reaffirmed their earnings growth forecast.

The company believes in the future growth of the life science industry and continues to develop its infrastructure to support those engaged in research in this field.